{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:36:11Z","timestamp":1765827371771,"version":"3.40.5"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,20]],"date-time":"2015-07-20T00:00:00Z","timestamp":1437350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jdcjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.jdiacomp.2015.07.020","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T16:14:26Z","timestamp":1437495266000},"page":"1203-1210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining \u03b2-cell function and achievement of HbA1c target one year after initiation"],"prefix":"10.1016","volume":"29","author":[{"given":"Ryota","family":"Usui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5334-7687","authenticated-orcid":false,"given":"Daisuke","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kuwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-9365","authenticated-orcid":false,"given":"Kenta","family":"Murotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kurose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Seino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jdiacomp.2015.07.020_bb0220","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.diabres.2004.10.005","article-title":"Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes","volume":"68","author":"Albareda","year":"2005","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"9131","key":"10.1016\/j.jdiacomp.2015.07.020_bb0030","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jdiacomp.2015.07.020_bb0020","first-page":"1249","article-title":"U.K. prospective diabetes study 16. Overview of 6years' therapy of type II diabetes: A progressive disease. U.K. Prospective Diabetes Study Group","volume":"44","year":"1999","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.jdiacomp.2015.07.020_bb0035","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2337\/dc11-1307","article-title":"Glycemic control over 5years in 4,900 people with type 2 diabetes: Real-world diabetes therapy in a clinical trial cohort","volume":"35","author":"Best","year":"2012","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.jdiacomp.2015.07.020_bb0005","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2337\/diab.37.6.667","article-title":"The triumvirate: \u03b2-Cell, muscle, liver. A collusion responsible for NIDDM","volume":"37","author":"DeFronzo","year":"1988","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.jdiacomp.2015.07.020_bb0100","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2337\/diab.26.7.605","article-title":"C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus","volume":"26","author":"Faber","year":"1977","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.jdiacomp.2015.07.020_bb0115","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1507\/endocrj.EJ14-0456","article-title":"Increment of serum C-peptide measured by glucagon test closely correlates with human relative beta-cell area","volume":"62","author":"Fujita","year":"2015","journal-title":"Endocrine Journal"},{"issue":"4","key":"10.1016\/j.jdiacomp.2015.07.020_bb0120","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.2040-1124.2010.00096.x","article-title":"Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patientes with type 2 diaebtes","volume":"2","author":"Funakoshi","year":"2011","journal-title":"Journal of Diabetes Investigation"},{"issue":"4","key":"10.1016\/j.jdiacomp.2015.07.020_bb0110","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/diacare.10.4.487","article-title":"Correlations between fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in insulin-treated diabetics","volume":"10","author":"Gjessing","year":"1987","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.jdiacomp.2015.07.020_bb0170","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.2337\/dc07-2451","article-title":"Type 1 Diabetes Trial Net Research G, et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes","volume":"31","author":"Greenbaum","year":"2008","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.jdiacomp.2015.07.020_bb0105","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/BF01236316","article-title":"Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-etide response to intravenous glucagon","volume":"13","author":"Hendriksen","year":"1977","journal-title":"Diabetologia"},{"issue":"15","key":"10.1016\/j.jdiacomp.2015.07.020_bb0025","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.jdiacomp.2015.07.020_bb0095","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jdiacomp.2012.07.001","article-title":"Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes","volume":"27","author":"Iwao","year":"2013","journal-title":"Journal of Diabetes and its Complications"},{"issue":"5","key":"10.1016\/j.jdiacomp.2015.07.020_bb0130","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/jdi.12181","article-title":"Secretory units of islets in transplantation index is a useful predictor of insulin requirement in Japanese type 2 diabetic patients","volume":"5","author":"Iwata","year":"2014","journal-title":"Journal of Diabetes Investigation"},{"issue":"1","key":"10.1016\/j.jdiacomp.2015.07.020_bb0165","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1507\/endocrj1954.26.65","article-title":"Human plasma C-peptide immunoreactivity: Its correlation with immunoreactive insulin in diabetes, and chronic liver and renal diseases","volume":"26","author":"Kajinuma","year":"1979","journal-title":"Endocrinologia Japonica"},{"issue":"4","key":"10.1016\/j.jdiacomp.2015.07.020_bb0175","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1463-1326.2009.01194.x","article-title":"Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human GLP-1 analogue liraglutide as add-on to sulfonylurea in Japanese patients with type 2 diabetes","volume":"12","author":"Kaku","year":"2010","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"6","key":"10.1016\/j.jdiacomp.2015.07.020_bb0180","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.2040-1124.2011.00128.x","article-title":"Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes","volume":"2","author":"Kaku","year":"2011","journal-title":"Journal of Diabetes Investigation"},{"issue":"6","key":"10.1016\/j.jdiacomp.2015.07.020_bb0150","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/jdi.12082","article-title":"Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes","volume":"4","author":"Kondo","year":"2013","journal-title":"Journal of Diabetes Investigation"},{"issue":"3","key":"10.1016\/j.jdiacomp.2015.07.020_bb0145","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.2040-1124.2011.00168.x","article-title":"Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity","volume":"3","author":"Kozawa","year":"2012","journal-title":"Journal of Diabetes Investigation"},{"issue":"3","key":"10.1016\/j.jdiacomp.2015.07.020_bb0085","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.clinthera.2014.11.015","article-title":"Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy","volume":"37","author":"Lapolla","year":"2015","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1016\/j.jdiacomp.2015.07.020_bb0160","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0168-8227(85)80006-1","article-title":"A comparison of serum C-peptide response to intravenous glucagon, and urine C-peptide, as indexes of insulin dependence","volume":"1","author":"Matsuda","year":"1985","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"12","key":"10.1016\/j.jdiacomp.2015.07.020_bb0040","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nature Reviews. Endocrinology"},{"issue":"Supplment 1","key":"10.1016\/j.jdiacomp.2015.07.020_bb0195","first-page":"S322","article-title":"Greater glycaemic control is achieved with the once-daily human GLP-1 analogue liraglutide vs comparators across the continuum of estimated beta cell mass","volume":"54","author":"Meier","year":"2011","journal-title":"Diabetologia"},{"issue":"Supplement1","key":"10.1016\/j.jdiacomp.2015.07.020_bb0200","first-page":"S357","article-title":"Efficacy of lixisenatide in patients with different levels of beta cell function as assessed by C-peptide\/glucose ratio","volume":"56","author":"Meier","year":"2013","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.jdiacomp.2015.07.020_bb0225","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF03348682","article-title":"The effect of various blood glucose levels on post-glucagon C-peptide secretion in type 2 (non insulin-dependent) diabetes","volume":"15","author":"Nosari","year":"1992","journal-title":"Journal of Endocrinological Investigation"},{"issue":"1","key":"10.1016\/j.jdiacomp.2015.07.020_bb0090","first-page":"103","article-title":"Long-term effectiveness and safety of liraglutide in clinical practice","volume":"38","author":"Ponzani","year":"2013","journal-title":"Minerva Endocrinologica"},{"issue":"12","key":"10.1016\/j.jdiacomp.2015.07.020_bb0070","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.2337\/dc14-0893","article-title":"Liraglutide and the preservation of pancreatic beta-cell function in early type 2 diabetes: The LIBRA trial","volume":"37","author":"Retnakaran","year":"2014","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.jdiacomp.2015.07.020_bb0125","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1507\/endocrj.K10E-399","article-title":"Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes","volume":"58","author":"Saisho","year":"2011","journal-title":"Endocrine Journal"},{"issue":"10","key":"10.1016\/j.jdiacomp.2015.07.020_bb0215","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"The Journal of Clinical Investigation"},{"issue":"5","key":"10.1016\/j.jdiacomp.2015.07.020_bb0155","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.2040-1124.2010.00074.x","article-title":"Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus","volume":"1","author":"Seino","year":"2010","journal-title":"Journal of Diabetes Investigation"},{"issue":"4","key":"10.1016\/j.jdiacomp.2015.07.020_bb0065","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.2040-1124.2012.00193.x","article-title":"The once-daily human glucagon-like peptide-1 analog, liraglutide, improves beta-cell function in Japanese patients with type 2 diabetes","volume":"3","author":"Seino","year":"2012","journal-title":"Journal of Diabetes Investigation"},{"issue":"5","key":"10.1016\/j.jdiacomp.2015.07.020_bb0185","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1185\/03007991003672551","article-title":"Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes","volume":"26","author":"Seino","year":"2010","journal-title":"Current Medical Research and Opinion"},{"issue":"4","key":"10.1016\/j.jdiacomp.2015.07.020_bb0190","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.2040-1124.2011.00103.x","article-title":"Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial","volume":"2","author":"Seino","year":"2011","journal-title":"Journal of Diabetes Investigation"},{"key":"10.1016\/j.jdiacomp.2015.07.020_bb0075","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.peptides.2013.11.011","article-title":"Early liraglutide treatment is better in glucose control, beta-cell function improvement and mass preservation in db\/db mice","volume":"52","author":"Shao","year":"2014","journal-title":"Peptides"},{"issue":"6","key":"10.1016\/j.jdiacomp.2015.07.020_bb0205","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1172\/JCI72434","article-title":"Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect","volume":"124","author":"Sisley","year":"2014","journal-title":"The Journal of Clinical Investigation"},{"issue":"9467","key":"10.1016\/j.jdiacomp.2015.07.020_bb0010","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0140-6736(05)61032-X","article-title":"Type 2 diabetes: Principles of pathogenesis and therapy","volume":"365","author":"Stumvoll","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jdiacomp.2015.07.020_bb0080","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.diabres.2014.09.052","article-title":"Predictors of response to liraglutide in Japanese type 2 diabetes","volume":"106","author":"Toyoda","year":"2014","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"6","key":"10.1016\/j.jdiacomp.2015.07.020_bb0140","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/jdi.12111","article-title":"Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced beta cell function","volume":"4","author":"Usui","year":"2013","journal-title":"Journal of Diabetes Investigation"},{"issue":"12","key":"10.1016\/j.jdiacomp.2015.07.020_bb0210","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.2337\/db14-0849","article-title":"GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans","volume":"63","author":"van Bloemendaal","year":"2014","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.jdiacomp.2015.07.020_bb0060","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1464-5491.2007.02333.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus","volume":"25","author":"Vilsboll","year":"2008","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.jdiacomp.2015.07.020_bb0050","first-page":"1","article-title":"Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: Assessment of composite end-points","author":"Yabe","year":"2015","journal-title":"Current Medical Research and Opinion"},{"key":"10.1016\/j.jdiacomp.2015.07.020_bb0055","first-page":"47","article-title":"Liraglutide in adults with type 2 diabetes: Global perspective on safety, efficacy and patient preference","volume":"4","author":"Yabe","year":"2011","journal-title":"Clinical Medicine Insights: Endocrinology and, Diabetes"},{"issue":"6","key":"10.1016\/j.jdiacomp.2015.07.020_bb0045","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1586\/17446651.2014.949672","article-title":"Defining the role of GLP-1 receptor agonists for individualized treatment of type 2 diabetes","volume":"9","author":"Yabe","year":"2014","journal-title":"Expert Review of Endocrinology and Metabolism"},{"issue":"6","key":"10.1016\/j.jdiacomp.2015.07.020_bb0015","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s11892-015-0602-9","article-title":"\u03b2 Cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians","volume":"15","author":"Yabe","year":"2015","journal-title":"Current Diabetes Reports"},{"issue":"3","key":"10.1016\/j.jdiacomp.2015.07.020_bb0135","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.diabres.2006.03.030","article-title":"SUIT, secretory units of islets in transplantation: An index for therapeutic management of islet transplanted patients and its application to type 2 diabetes","volume":"74","author":"Yamada","year":"2006","journal-title":"Diabetes Research and Clinical Practice"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872715002925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872715002925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T15:50:56Z","timestamp":1537458656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872715002925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1056872715002925"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2015.07.020","relation":{},"ISSN":["1056-8727"],"issn-type":[{"type":"print","value":"1056-8727"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining \u03b2-cell function and achievement of HbA1c target one year after initiation","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2015.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}